Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
XENE Stock Chart & Stats
$43.79
-$0.78(-1.91%)
At close: 4:00 PM EST
$43.79
-$0.78(-1.91%)
Day’s Range― - ―
52-Week Range$26.74 - $46.99
Previous CloseN/A
Volume41.45K
Average Volume (3M)811.05K
Market Cap
$3.64B
Enterprise Value$3.14B
Total Cash (Recent Filing)$548.89M
Total Debt (Recent Filing)$7.94M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
May 12, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding83,190,315
10 Day Avg. Volume938,639
30 Day Avg. Volume811,047
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)6.11
Price to Sales (P/S)473.62
P/FCF Ratio-12.69
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue418.06
Enterprise Value/Gross Profit-44.29
Enterprise Value/Ebitda-8.73
Forecast
1Y Price Target
$55.92Price Target Upside27.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.85
Revenue Forecast (FY)$5.84M
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationAzetukalner's once daily dosing, lack of titration requirement, rapid onset, and limited drug interactions present clear clinical advantages that could drive adoption by general neurologists if efficacy is confirmed.
Competitive PositioningRepeated clinical setbacks for a competing Kv7 modulator reduce the chance of near term rival success and strengthen azetukalner's relative commercial and clinical outlook.
Regulatory PathwayAnalyst states that a favorable pivotal phase three readout for azetukalner could enable a regulatory filing and materially improve the company's approval prospects and valuation.
Bears Say
Concentration RiskStock performance is heavily tied to the outcome of the pivotal X‑TOLE2 trial, creating substantial downside risk if the study does not meet expectations.
Efficacy And Placebo Trend RiskPublished analyses and historical trial patterns indicate rising placebo responses and the potential for efficacy to diminish between early and later studies, increasing the chance of a weaker pivotal readout than earlier data suggested.
Patient Composition RiskA meaningful portion of trial participants have prior cenobamate exposure, which could elevate placebo responses and complicate the interpretation of efficacy signals.
Xenon News
XENE FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was $26.74 and its highest was $46.99 in the past 12 months.
What is Xenon’s market cap?
Xenon’s market cap is $3.64B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is May 12, 2026 which is in 68 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on Feb 26, 2026. The company reported -$1.31 earnings per share for the quarter, missing the consensus estimate of -$1.192 by -$0.118.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -1.2.
How many shares outstanding does Xenon have?
Xenon has 83,190,315 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$1.31 in its last earnings report, missing expectations of -$1.192. Following the earnings report the stock price went down -3.762%.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in XENE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xenon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.92 (27.70% Upside)
$55.92 (27.70% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 603.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
News Sentiment
Very Bullish
Bullish news 90%
Bearish news 10%
Bearish news 10%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.35%
12-Months-Change
Fundamentals
Return on Equity
-51.76%
Trailing 12-Months
Asset Growth
-8.00%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
XENE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in Xenon's late-stage and early-stage clinical programs, particularly for azetukalner in epilepsy and neuropsychiatric disorders. Financially, the company is well-positioned to support its operations and pipeline development. While challenges exist, such as increased competition and screening hurdles, the positive advancements and robust financial health contribute to an overall optimistic outlook.View all XENE earnings summariesXENE Stock 12 Month Forecast
Average Price Target
$55.92
▲(27.70% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Scholar Rock Holding
―
Immunovant
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
0.10% Insiders
31.47% Mutual Funds
51.97% Other Institutional Investors
10.30% Public Companies and
Individual Investors